These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 34737259)
1. Gold nanoparticles enhance antibody effect through direct cancer cell cytotoxicity by differential regulation of phagocytosis. Fan L; Wang W; Wang Z; Zhao M Nat Commun; 2021 Nov; 12(1):6371. PubMed ID: 34737259 [TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402 [TBL] [Abstract][Full Text] [Related]
4. Ramucirumab: first global approval. Poole RM; Vaidya A Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147 [TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells. Li YF; Zhang HT; Xin L J Cancer Res Clin Oncol; 2018 Aug; 144(8):1463-1473. PubMed ID: 29858680 [TBL] [Abstract][Full Text] [Related]
6. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Javle M; Smyth EC; Chau I Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695 [TBL] [Abstract][Full Text] [Related]
7. Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature. Takada J; Araki H; Ozawa N; Sugiyama T; Kubota M; Ibuka T; Shimizu M J Gastrointest Cancer; 2019 Sep; 50(3):556-559. PubMed ID: 29250745 [No Abstract] [Full Text] [Related]
8. Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles. Ahmed M; Pan DW; Davis ME Bioconjug Chem; 2015 May; 26(5):812-6. PubMed ID: 25879583 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. Huang W; Xing Y; Zhu L; Zhuo J; Cai M Exp Cell Res; 2021 Sep; 406(1):112633. PubMed ID: 34089726 [TBL] [Abstract][Full Text] [Related]
10. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Karmani L; Labar D; Valembois V; Bouchat V; Nagaswaran PG; Bol A; Gillart J; Levêque P; Bouzin C; Bonifazi D; Michiels C; Feron O; Grégoire V; Lucas S; Vander Borght T; Gallez B Contrast Media Mol Imaging; 2013; 8(5):402-8. PubMed ID: 23740810 [TBL] [Abstract][Full Text] [Related]
11. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT). Wu CY; Lin JJ; Chang WY; Hsieh CY; Wu CC; Chen HS; Hsu HJ; Yang AS; Hsu MH; Kuo WY Colloids Surf B Biointerfaces; 2019 Nov; 183():110387. PubMed ID: 31394419 [TBL] [Abstract][Full Text] [Related]
12. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411 [TBL] [Abstract][Full Text] [Related]
13. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer. Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782 [TBL] [Abstract][Full Text] [Related]
14. Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models. Shiravi F; Mohammadi M; Golsaz-Shirazi F; Bahadori T; Judaki MA; Fatemi F; Zare HA; Haghighat FN; Mobini M; Jeddi-Tehrani M; Amiri MM; Shokri F Invest New Drugs; 2021 Jun; 39(3):697-704. PubMed ID: 33389387 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of galactoxyloglucan-gold nanoparticles against murine ascites and solid carcinoma. Joseph MM; Aravind SR; George SK; Pillai KR; Mini S; Sreelekha TT Colloids Surf B Biointerfaces; 2014 Apr; 116():219-27. PubMed ID: 24486833 [TBL] [Abstract][Full Text] [Related]
16. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362 [TBL] [Abstract][Full Text] [Related]
17. Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer. Wu JQ; Fan RY; Zhai J; Li CY; Wei P; Shen LZ; He MF; Wang P; Huang XE Life Sci; 2022 May; 296():120439. PubMed ID: 35235851 [TBL] [Abstract][Full Text] [Related]
18. ImmunoPET Imaging of Pancreatic Tumors with Sobol NB; Korsen JA; Younes A; Edwards KJ; Lewis JS Mol Imaging Biol; 2021 Feb; 23(1):84-94. PubMed ID: 32909244 [TBL] [Abstract][Full Text] [Related]
19. Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo. Lu L; Li K; Mao YH; Qu H; Yao B; Zhong WW; Ma B; Wang ZY Int J Oncol; 2017 Oct; 51(4):1089-1103. PubMed ID: 28849003 [TBL] [Abstract][Full Text] [Related]
20. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Glazer ES; Zhu C; Massey KL; Thompson CS; Kaluarachchi WD; Hamir AN; Curley SA Clin Cancer Res; 2010 Dec; 16(23):5712-21. PubMed ID: 21138869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]